<DOC>
	<DOCNO>NCT01806597</DOCNO>
	<brief_summary>Purpose study demonstrate efficacy secukinumab versus placebo palmoplantar psoriasis ass long term efficacy , safety tolerability secukinumab .</brief_summary>
	<brief_title>Study Safety , Tolerability , Efficacy Secukinumab Subjects With Moderate Severe Palmoplantar Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Subjects chronic , moderate severe plaque type psoriasis least 6 month prior randomization significant involvement palm sol baseline , define palmoplantar Investigator 's Global Assessment ( ppIGA ) score ≥ 3 5point scale , well least one skin plaque baseline palmoplantar area Candidates systemic therapy , i.e . psoriasis inadequately control topical treatment ( include super potent topical corticosteroid ) and/or phototherapy and/or previous systemic therapy Forms psoriasis chronic plaque type psoriasis ( e.g. , pustular psoriasis , palmoplantar pustulosis , acrodermatitis Hallopeau , erythrodermic guttate psoriasis ) Druginduced psoriasis ( e.g . new onset current exacerbation βblockers , calcium channel inhibitor lithium ) Ongoing use prohibit treatment ( e.g . topical systemic corticosteroid ( CS ) , UV therapy ) . Washout period apply . Prior exposure secukinumab ( AIN457 ) biological drug directly target IL17 IL17 receptor Use investigational drug within 4 week prior study treatment initiation within period 5 halflives investigational treatment , whichever longer Active ongoing inflammatory disease psoriasis might confound evaluation benefit secukinumab therapy History hypersensitivity constituent study treatment Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Moderate palmoplantar psoriasis</keyword>
	<keyword>Severe palmoplantar psoriasis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>Secukinumab</keyword>
</DOC>